Lateral Flow Assays (LFAs) are a elegant, ultra-cheap diagnostic test format with hundreds of applications. Unfortunately, their simplicity limits their sensitivity.
At AfimaCheck, we are developing a game-changing assay reader that greatly improves the LFA level-of-detection and accuracy relative to visual/optical interpretation.
Our patented technology is capable of measuring THC in oral fluids at concentrations 2ng/ml with 98% accuracy - well below existing roadside and workplace solutions.
Proven 10x improvement in level of detection vs. commercially available tests.
Delivers quantitative results less than a minute - eliminating imprecise , error-prone visual interpretation.
Patented technology enhances the capabilities of any lateral flow assay without altering chemistry.
ON-SITE ORAL FLUID TESTING FOR CANNABIS USE
DETECTION OF SARS-COVID2 WITHIN 6 DAYS OF INFECTION
HERD HEALTH MONITORING AND AFLATOXIN DETECTION
POINT-OF-NEED DEVICES FOR ALLERGENS AND PATHOGENS
RAPID SCREENING FOR DISEASE BIOMARKERS
RAPID TESTING FOR THC OTHER DOA IN ORAL FLUIDS
Ensuring that drivers are not under the influence is more important than ever given widespread cannabis legalization. The ultra-portable AfimaCheck reader can rapidly test saliva for several drugs-of-abuse at levels relevant to reasonable suspicion as part of a SFST.
The AfimaCheck Reader empowers workplace drug testing for safety-sensitive duties. Our technology is able to detect and quantify the presence of cannabis in oral fluid at concentrations as low as 2ng/ml with 96% accuracy.
Our patented thermophotonic lock-in technology allows quantitative measurements of existing Lateral Flow Assays. We are unlocking unprecedented detection sensitivity in low-cost paper-based testing.